

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this joint announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this joint announcement.

This joint announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of Huakang Biomedical Holdings Company Limited nor is it a solicitation of any acceptance, vote or approval in any jurisdiction.

ANSELME LIMITED

(Incorporated in the British Virgin Islands with limited liability)



HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED

華康生物醫學控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 8622)

**JOINT ANNOUNCEMENT
DELAY IN DESPATCH OF THE COMPOSITE DOCUMENT
RELATING TO MANDATORY UNCONDITIONAL CASH OFFERS BY**



**FOR AND ON BEHALF OF ANSELME LIMITED
TO ACQUIRE ALL THE ISSUED SHARES OF AND
TO CANCEL ALL OUTSTANDING SHARE OPTIONS OF
HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED
(OTHER THAN THOSE ALREADY OWNED OR
AGREED TO BE ACQUIRED BY ANSELME LIMITED AND
PARTIES ACTING IN CONCERT WITH IT)**

Joint Financial Advisers to Anselme Limited



Capital 9 Limited

Independent Financial Adviser to the Independent Board Committee



Reference is made to the announcement jointly published by the Offeror and the Company dated 9 October 2025 in relation to, among others, the Sale and Purchase Agreement and the Offers (the “**Joint Announcement**”). Unless otherwise stated, terms used in this joint announcement shall have the same meanings as those defined in the Joint Announcement.

DELAY IN DESPATCH OF THE COMPOSITE DOCUMENT

As disclosed in the Joint Announcement, it is the intention of the Offeror and the Company to combine the offer document and the offeree board circular into the Composite Document and be jointly despatched by the Offeror and the Company to the Offer Shareholders and the Offer Optionholders. Pursuant to Rule 8.2 of the Takeovers Code, the Composite Document containing, among other things, (i) the terms of the Offers; (ii) the recommendation from the Independent Board Committee to the Offer Shareholders and the Offer Optionholders; and (iii) the advice from the Independent Financial Adviser in respect of the Offers, together with the Form(s) of Acceptance, will be despatched to the Offer Shareholders and the Offer Optionholders on or before 30 October 2025 in accordance with the Takeovers Code, or such other date as the Executive may approve.

As additional time is required to finalise certain content of the Composite Document (including but not limited to the latest unaudited management accounts of the Group for the statement on material changes in the financial or trading position or outlook of the Group pursuant to Rule 10.11 of the Takeovers Code and certain financial information of the Group), an application has been made to the Executive for a waiver from strict compliance with the requirements under Rule 8.2 of the Takeovers Code. The Executive has indicated that it is minded to grant consent to extend the latest time for the despatch of the Composite Document (together with the accompanying Forms of Acceptance) to a date falling on or before 20 November 2025.

Further announcement(s) in relation to the despatch of the Composite Document will be made by the Offeror and the Company as and when appropriate.

By order of the Board
Anselme Limited
Zhou Xunyong
Sole Director

By order of the Board
Huakang Biomedical Holdings Company Limited
Zhang Yujing
Chairman and Executive Director

Hong Kong, 28 October 2025

As at the date of this joint announcement, Dr. Zhou Xunyong is the sole director of the Offeror. As the sole director of the Offeror, Dr. Zhou Xunyong accepts full responsibility for the accuracy of the information contained in this joint announcement (other than that relating to the Vendor and the Group) and confirm, having made all reasonable inquiries, that to the best of his knowledge, opinions expressed in this joint announcement (other than that expressed by the Directors) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement, the omission of which would make any statements in this joint announcement misleading.

As at the date of this announcement, the Executive Directors are Ms. Zhang Yujing, Mr. Zhang Chunguang and Mr. Poon Lai Yin Michael; the Non-executive Directors are Dr. Bu Su and Dr. Xu Ming; and the Independent Non-executive Directors are Dr. Chow Kwok Fai Joseph, Ms. Wang Yachun and Mr. Tsui Wing Tak. The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this joint announcement (other than those relating to the Offeror) and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this joint announcement (other than those expressed by the director of the Offeror in their capacity as such) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement, the omission of which would make any statements in this joint announcement misleading.

This joint announcement will remain on the “Latest Listed Company Information” page of the Stock Exchange website at www.hkexnews.hk for at least seven days from the date of publication and on the Company’s website at www.huakangbiomedical.com.